The CounterACT Program is offering this grant to establish Research Centers of Excellence (U54s) focused on developing new and improved therapeutics for chemical threats. This grant is for fostering research against toxic chemicals, including warfare agents, industrial chemicals, and pesticides, that could be used in attacks or released accidentally. The scope covers initial target identification through candidate optimization and demonstrating in vivo efficacy for human use. Renewing applicants should aim for an optimized lead compound ready for advanced development. Centers must comprise at least three research projects, supported by administrative, optional scientific, and research education cores. Each project needs clear milestones for translational study decisions.
Opportunity ID: 330538
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-20-316 |
| Funding Opportunity Title: | Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54 Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Environment Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.113 — Environmental Health |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Dec 21, 2020 |
| Last Updated Date: | Dec 21, 2020 |
| Original Closing Date for Applications: | Sep 12, 2023 |
| Current Closing Date for Applications: | Sep 12, 2023 |
| Archive Date: | Oct 18, 2023 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $1,750,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | City or township governments County governments Others (see text field entitled “Additional Information on Eligibility” for clarification) Small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities Public and State controlled institutions of higher education For profit organizations other than small businesses State governments Private institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts Native American tribal governments (Federally recognized) Special district governments |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This Funding Opportunity Announcement (FOA) encourages applications for Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54s). The mission of the CounterACT program is to foster and support research and development of new and improved therapeutics for chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, pharmaceutical-based agents, and pesticides. The scope of the research includes target and candidate identification and characterization, through candidate optimization and demonstration of in vivo efficacy consistent with the product’s intended use in humans. For applicants submitting U54 renewal applications, research under this FOA should culminate in an optimized lead compound ready for advanced development. The Centers will contain at least three research projects supported by an administrative core, up to three optional scientific cores, and a research education core. Each research project must include milestones that create discrete go or no-go decision points in a progressive translational study plan. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-20-316.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 330538 Full Announcement-PAR-20-316 -> PAR-20-316-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-F | Use for due dates on or before January 24, 2022 | PKG00264597 | Aug 14, 2021 | Jan 24, 2022 | View | |
| FORMS-G | Use for due dates on or before January 24, 2023 | PKG00269620 | Oct 27, 2021 | Jan 24, 2023 | View | |
| FORMS-H | Use for due dates on or after January 25, 2023 | PKG00277486 | Oct 27, 2022 | Sep 12, 2023 | View |
Package 1
Mandatory forms
330538 RR_SF424_2_0-2.0.pdf
330538 PHS398_CoverPageSupplement_5_0-5.0.pdf
330538 RR_OtherProjectInfo_1_4-1.4.pdf
330538 PerformanceSite_2_0-2.0.pdf
330538 RR_KeyPersonExpanded_2_0-2.0.pdf
330538 PHS398_ResearchPlan_4_0-4.0.pdf
330538 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf
Optional forms
330538 PHS_Additional_IndirectCosts-1.0.pdf
330538 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 2
Mandatory forms
330538 RR_SF424_5_0-5.0.pdf
330538 PHS398_CoverPageSupplement_5_0-5.0.pdf
330538 RR_OtherProjectInfo_1_4-1.4.pdf
330538 PerformanceSite_4_0-4.0.pdf
330538 RR_KeyPersonExpanded_4_0-4.0.pdf
330538 PHS398_ResearchPlan_4_0-4.0.pdf
330538 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
330538 PHS_Additional_IndirectCosts_2_0-2.0.pdf
330538 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 3
Mandatory forms
330538 RR_SF424_5_0-5.0.pdf
330538 PHS398_CoverPageSupplement_5_0-5.0.pdf
330538 RR_OtherProjectInfo_1_4-1.4.pdf
330538 PerformanceSite_4_0-4.0.pdf
330538 RR_KeyPersonExpanded_4_0-4.0.pdf
330538 PHS398_ResearchPlan_5_0-5.0.pdf
330538 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
330538 PHS_Additional_IndirectCosts_2_0-2.0.pdf
330538 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
